



HAL
open science

Rational De Novo Design of a Cu-Metalloenzyme for Superoxide Dismutation

Emilie Mathieu, Audrey Tolbert, Karl Koebke, Cédric Tard, Olga Iranzo, James Penner-hahn, Clotilde Policar, Vincent Pecoraro

► **To cite this version:**

Emilie Mathieu, Audrey Tolbert, Karl Koebke, Cédric Tard, Olga Iranzo, et al.. Rational De Novo Design of a Cu-Metalloenzyme for Superoxide Dismutation. *Chemistry - A European Journal*, 2020, 26 (1), pp.249-258. 10.1002/chem.201903808 . hal-02402535

HAL Id: hal-02402535

<https://hal.science/hal-02402535>

Submitted on 14 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Rational *De Novo* Design of a Cu-Metalloenzyme for Superoxide Dismutation

Emilie Mathieu^{[b][e]}, Audrey E. Tolbert^{[a][e]}, Karl J. Koebke^[a], Cédric Tard^[c], Olga Iranzo^[d], James E. Penner-Hahn^[a], Clotilde Policar^{[b]*}, and Vincent Pecoraro^{[a]*}

Abstract: Superoxide dismutases (SODs) are highly efficient enzymes for superoxide dismutation and the first line of defense against oxidative stress. These metalloproteins contain a redox active metal ion in their active site (Mn, Cu, Fe, Ni) with a tightly controlled reduction potential found in a close range around the optimal value of 0.36 V vs. NHE. Rationally designed proteins with well-defined three-dimensional structures offer new opportunities for obtaining functional SOD mimics. Here we explore four different copper binding scaffolds: H₃ (His₃), H₄ (His₄), H₂DH (His₃Asp with 2 His and 1 Asp in the same plane) and H₃D (His₃Asp with 3 His in the same plane) using the scaffold of the *de novo* protein GR α_3 D. EPR and XAS analysis of the resulting copper complexes demonstrates that they are good Cu(II) bound structural mimics of Cu-only SODs. Furthermore, all the complexes exhibit SOD activity, though three orders of magnitude slower than the native enzyme, making them the first *de novo* copper SOD mimics.

Introduction

Superoxide dismutases (SODs) are highly conserved metalloenzymes that have evolved to protect organisms from oxidative stress.^{1,2} Four types of SOD have been identified, but only three have been extensively studied (Table 1).^{1,3} The first well characterized class of SODs is the Fe/MnSOD, which can function with iron only, manganese only, or either metal in the case of cambialistic enzymes. These proteins have high sequence identity and the same His₃Asp metal binding site regardless of the active metal.⁴ The second is the NiSOD, which contains a His₂Cys binding site.⁵ The third type of well characterized SODs are Cu/ZnSODs. General features of

Cu/ZnSODs include a Greek key β -barrel backbone, an electrostatic loop, a disulfide bond, and a conserved active site.¹⁻³ In its reduced state, the catalytic copper is bound by three histidines in a trigonal plane. Upon oxidation, the Cu(II) is bound in a distorted square pyramid by an additional, bridging histidine and a water molecule. The bridging histidine also binds to the structural zinc ion, which is further coordinated by two other histidines and an aspartate.¹ Interestingly, a fourth class of SOD, Cu-only SOD, has recently been described containing a single copper metal ion in the active site.⁶⁻¹⁰ In these enzymes, the two histidines chelating the zinc ion in Cu/Zn SOD are missing, either due to substitution or deletion. Thus, the active site contains only four histidines capable of chelating copper. All four His residues coordinate Cu(II) in a pseudotrigonal pyramid, while Cu(I) is coordinated by only three His residues in a pseudotrigonal planar arrangement with the fourth His at a longer distance.¹¹ In *C. albicans* Cu-only SOD5, the role of the zinc ion in promoting pH-independent catalysis is adopted by a glutamate residue (Glu110) that interacts through H-bonding with the bridging histidine.¹⁰

Table 1. Summary of SOD activities.

SOD	Activity (M ⁻¹ s ⁻¹)	pH
Fe ¹²	3.25x10 ⁹	7.8
Mn ¹²	3.78x10 ⁹	7.8
Ni ¹³	1.3x10 ⁹	7.0
Cu/Zn ¹¹	1.2x10 ⁹	7.0
Cu only ¹¹	1.8x10 ⁹	6.0
	1.1x10 ⁹	7.25
Cyclodextran (Cu/Zn) ¹⁴	9.90x10 ⁷	7.8
N-term Cu/Zn model HADHDHKK ¹⁵	2.7x10 ⁷	7.0

Despite their differences in structure, active site, and metal center, all SODs catalyze superoxide dismutation at diffusion limited rates between pH 4 and 10.¹ Their reduction potentials are tightly controlled and fall in a close range around the optimal value of 0.36 V vs. NHE at physiological pH, corresponding to the midpoint potential between the oxidation (-0.18 V vs. NHE) and the reduction (+0.91 vs. NHE) of superoxide.¹

[a] Department of Chemistry
University of Michigan
Ann Arbor, MI 48103
E-mail: vlpec@umich.edu

[b] Laboratoire des biomolécules, LBM, Département de chimie
École normale supérieure, PSL University, Sorbonne Université,
CNRS
75005 Paris, France
E-mail: clotilde.policar@ens.fr

[c] LCM, CNRS, Ecole Polytechnique, IP Paris
F-91128 Palaiseau, France

[d] Aix Marseille Univ, CNRS, Centrale Marseille, iSm2
Marseille, France

[e] These authors contributed equally to this work
* Corresponding author

Low-molecular weight complexes mimicking SOD with a manganese, iron, or copper metal ion have been thoroughly described in the literature.^{2, 16-24} The challenges faced in their design include stability, flexibility to adapt to coordination of different metal redox states, and tuning the reduction potential to enable superoxide dismutation. For Cu/Zn SOD mimics, cyclodextrin^{22, 25} and bisdioxocyclan derivatives^{26, 27} are among the most efficient SOD mimics reported, with k_{cat} only ten fold lower than that of the native enzyme under similar conditions. Peptidic Cu/Zn SOD mimics have also been studied,^{15, 28-36} with the aim to reproduce the active site of the enzyme using short sequences of amino acids (3 to 10 residues) that contain two to four histidine moieties. One of the most active peptidic mimics of Cu/ZnSOD was reported by Árus *et al.*¹⁵ These unstructured peptide sequences contain three histidines (HADHDHKK) and bind copper in a 1:1 ratio. At pH 7.0 its k_{cat} is $2.7 \cdot 10^7 \text{ M}^{-1}\text{s}^{-1}$, which is only two orders of magnitude lower than that of the native Cu/Zn SOD. As many of these peptidic models are mononuclear Cu catalysts, they can provide some amount of insight into the Cu-only SOD system, but no models of Cu-only SOD have previously been described.

Widening possibilities beyond low-molecular weight complexes, rationally designed self-assembling peptidic scaffolds with well-defined secondary and tertiary structures are tools of choice to mimic the structure and activity of an enzyme.³⁷⁻⁴⁵ Only one manganese SOD mimic has been reported using this type of construct with modest SOD activity ($k_{\text{cat}} = 3.7 \cdot 10^5 \text{ M}^{-1}\text{s}^{-1}$ at pH 7.4).⁴⁶ Using protein redesign Benson *et al.* have obtained a functional iron SOD mimic by introducing a His₃ metal binding site and a pocket for O₂ binding into *E. coli* thioredoxin ($k_{\text{cat}} = 6.4 \cdot 10^6 \text{ M}^{-1}\text{s}^{-1}$ at pH 8).^{47, 48}

Herein, the GR α_3 D *de novo* protein scaffold was used to design a functional mimic of Cu-only SOD. The α_3 D family of proteins, originally designed by DeGrado *et al.*, consists of seven amino acid repeats in which the first and fourth residue of each heptad is hydrophobic.⁴⁹ In solution these hydrophobic residues collapse to form the core of an antiparallel three helix bundle.^{50, 51} Metal binding residues can then be introduced into this core to construct metalloproteins, though a loss of stability is incurred.⁵²⁻⁵⁴ This scaffold has previously been used to study both electron transfer proteins, such as cupredoxins and rubredoxins, and catalytic proteins, such as carbonic anhydrase.^{52, 54-57} An elongated version of this peptide, GR α_3 D, was designed with an additional heptad for improved thermodynamic stability.⁵⁸ Four binding sites were introduced into the protein; H₃ (His₃), H₄ (His₄), H₂DH (His₃Asp with two His and one Asp in the same plane), and H₃D

(His₃Asp with three His in the same plane) (Table 2). The stability of the apo- and Cu(II)-protein was studied by thermal denaturation and the complexes were characterized by EPR, EXAFS, and CV experiments. Their SOD activity was assessed by the indirect assay of McCord-Fridovich.⁵⁹⁻⁶¹

Peptide	Sequence
GR α_3 D H ₃	MGSWAEFKQLAAIKTRLAAIKSRHDLGGSEAELEAAHEKEIAAFESEIAAFESLQAYKGG-NPEVEALRKEAAAIRDEAAAIRDEHQAYRLNGSGA/C
GR α_3 D H ₄	MGSWAEFKQLAAIKTRLAAIKSRHDLGGSEAEHAAHEKEIAAFESEIAAFESLQAYKGG-NPEVEALRKEAAAIRDEAAAIRDEHQAYRLNGSGA/C
GR α_3 D H ₂ DH	MGSWAEFKQLAAIKTRLAAIKSRHDLGGSEAEHAADEKEIAAFESEIAAFESLQAYKGG-NPEVEALRKEAAAIRDEAAAIRDEHQAYRLNGSGA/C
GR α_3 D H ₃ D	MGSWAEFKQLAAIKTRLAAIKSRHDLGGSEAEDEAAHEKEIAAFESEIAAFESLQAYKGG-NPEVEALRKEAAAIRDEAAAIRDEHQAYRLNGSGA/C

Results

Protein Design

Four constructs were built within the GR α_3 D *de novo* protein scaffold with varying active sites meant to recapitulate that of two different classes of SODs, Cu only SOD and Fe/Mn SOD. Their sequences are listed in Table 2. Constructs with an A98C mutation were used for electrochemical experiments. The four different active sites designed within GR α_3 D for this study are represented in Figure 1. GR α_3 D H₃ contains three histidines that replace leucine or phenylalanine (L25H, F38H, L88H) in positions analogous to the carbonic anhydrase mimic α_3 DH₃, which also models the Cu(I) binding site of Cu only SOD.⁵² GR α_3 D H₄ contains a fourth histidine in position 35 (L35H) to mimic the Cu(II) binding site of Cu-only SOD.^{6, 7} Constructs in which the fourth His residue was substituted by an Asp were created to test the effects of modulating the reduction potential of the bound Cu. To this end GR α_3 D H₂DH and GR α_3 D H₃D, in which the Asp is either




Figure 1. PyMol models of the designed His₃ (H₃), His₄ (H₄), His₂AspHis (H₂DH), and His₃Asp (H₃D) active sites within GR α_3 D based on the crystal structure of GR α_3 D (PDB: 6DS9).

FULL PAPER

positioned in the same plane as two other His (L38D), or below a plane constituted by the three His (L35D), respectively, were designed. These constructs also model the active site of Fe/Mn SOD, providing interesting insight into the selectivity and catalytic efficiency of substituting copper into this system

Thermal stability of the apo- and Cu(II)-proteins

CD spectra of the apo-proteins were obtained to test whether GR α_3 D could properly fold with four large hydrophilic metal binding residues mutated into the hydrophobic core (Figure S1). The double minima bands at 208 and 222 nm are representative of α -helical secondary structure and indicate a well folded three helical bundle peptide.^{62, 63} We next sought to compare the destabilization effects of the differing active sites. Thermal denaturation of apo- and Cu(II)-proteins were studied and compared to that of GR α_3 D by following the ellipticity of the proteins at 222 nm at varying temperatures. The midpoint of unfolding (T_M) was determined by fitting the data to a two state unfolding model using the program CDpal.⁶³⁻⁶⁵ These values are summarized in Table 3.


GR α_3 D is structurally stable in the range of temperature used with a melting temperature above 95 °C, which precludes calculating the aforementioned thermodynamic parameters. Three of the four constructs reported within this study, however, have melting temperatures below 95 °C, allowing for their direct measurement. Comparing these four constructs, we find that addition of a fourth residue destabilizes the protein as the T_M decreases over 10 °C between GR α_3 D H₃ (T_M >95 °C), and GR α_3 D H₂DH, H₃D, and H₄ (T_M ~80 °C). Cu(II) bound peptide is more thermodynamically stable than the apo peptide, with T_M increasing by 5 to 10 °C depending on the construct. Overall, the data assess that the apo-proteins and the Cu(II) complexes are well folded at room temperature.

Interestingly, GR α_3 D H₄ shows two steps in the unfolding process in both the apo and Cu(II) bound forms (Figure 2). The first transition to an intermediate state occurs at 55 °C. The second step occurs between 70 °C and 90 °C, similar to the other constructs. Upon cooling, the first state is no longer observed and reheating a sample results in a similar denaturation profile to the renaturation profile (Figure S2).

Cu(II)-protein XAS and EPR characterization

X-ray Absorption Spectroscopy (XAS), consisting of both X-ray absorption near edge structure (XANES) and extended X-ray absorption fine structure (EXAFS), was done on Cu(II)-GR α_3 D H₃, Cu(II)-GR α_3 D H₄, Cu(II)-GR α_3 D H₂DH, and Cu(II)-GR α_3 D H₃D and analyzed to investigate the structural differences between these four SOD mimics (Figure 3). The average nearest neighbor bond distance was between 1.94 and 1.95 Å for all constructs analyzed, consistent with 4-coordinate N or O bound Cu(II) (Table 4).

Figure 2. Thermal denaturation circular dichroism fits of GR α_3 D H₃D, H₂DH, H₃, and H₄ (top to bottom). Apo spectra are shown with black circles and Cu(II) bound spectra with red squares. Only the second denaturation step was fit for GR α_3 D H₄.



FULL PAPER

All constructs exhibit long distance backscatters, which best fit to 3 His ligands. All fits attempted are included within the supporting information. This apparent similarity between the four constructs'

structures also extended to XANES analysis, where the 1s → 3d transitions (peak at 8979 eV) for all four constructs were of similar height indicating an equivalent degree of tetrahedral character to their geometry.^{66, 67}

Table 3. Thermodynamic parameters of unfolding for apo- and Cu(II)-GR α_3 D three-helix bundles determined by thermal denaturation.

Peptide	Apo peptide T _M (°C)	Cu peptide T _M (°C)
GR α_3 D	>95	N/A
GR α_3 D H ₂ DH	79.8 ± 0.7	85.1 ± 0.9
GR α_3 D H ₃ D	80.6 ± 0.6	88 ± 6
GR α_3 D H ₃	>95	>95
GR α_3 D H ₄	83.21 ± 0.01	93.8 ± 0.5

EPR spectra of Cu(II)-proteins were collected in 50 mM HEPES buffer, pH 7.5 at 100 K with a 2:1 protein/Cu(II) ratio to ensure that all copper is bound (Figure 4). The *g* values and hyperfine coupling constants of the Cu(II) complexes were determined by fitting with the SpinCount software and are listed in Table 5.⁶⁸ Each complex has anisotropic *g* values with *g_x*, *g_y* < *g_z* characteristic of a d_{x²-y²} SOMO.⁶⁹ Together with EXAFS data, the results suggest 4-coordinate copper complexes in a distorted square planar geometry.⁶⁹ Two distinct species (A and B in Table 5) are observed in the EPR spectra of Cu(II)-GR α_3 D H₃ and Cu(II)-GR α_3 D H₄. Simulation of the EPR spectrum of GR α_3 D H₃ shows that form A is dominant and accounts for 75% of the signal




Figure 3. 1s → 3d region of Cu(II) XANES at pH 7.5 for every construct reported.




Figure 4. Electron Paramagnetic Resonance spectra of the constructs presented in this study recorded at pH 7.5. Fits were done using the program SpinCount.

observed, whereas form B accounts for 25%. For GR α_3 D H₄ the two species are present in the same ratio. The EPR parameters of a Cu-only SOD found in *Mycobacterium tuberculosis* (His₄ active site) and a copper-substituted FeSOD from the archaeon *Acidianus ambivalens* (His₂AspHis) are given in Table 5.^{7, 70} The

Table 4. Cu(II) EXAFS and XANES fitting parameters at pH 7.5

Construct	Model	Cu-O/N* R Å	Cu-O/N* σ^2 10 ⁻³ Å ²	Cu-Imid R Å	Cu-Imid σ^2 10 ⁻³ Å ²	Avg. bond length Å	1s→3d area
GR α_3 D H ₃	His ₃ O ₁	1.966	5.7	1.935	13.28	1.943	8.27
GR α_3 D H ₄	His ₃ N ₁	1.881	4.4	1.972	6.23	1.949	6.89
GR α_3 D H ₂ DH	His ₃ O ₁	1.981	1.5	1.933	8.06	1.945	5.41
GR α_3 D H ₃ D	His ₃ O ₁	1.989	2.0	1.933	7.86	1.947	3.09

Cu(II)-GR α_3 D derivatives have g values similar to these native enzymes and slightly higher $A_{||}$ values.

One may also attempt to correlate the hyperfine coupling constant observed in EPR to variation in activity between the constructs reported. The empirical factor $f = g_z/A_{||}$ correlates with tetrahedral distortions where values between 105 to 135 cm are indicative of square planar geometry and higher values indicate distortion towards tetrahedral structures.^{71, 72} According to the values in table 5, our constructs are more tetragonal than native examples, which may be correlated to the decreased activity compared to native enzymes. This is bolstered by the case of GR α_3 D H₄ in which two species are evident at a 1:1 ratio. The GR α_3 D H₄ species B has an f factor of 119.6 cm, indicating that this species is more tetragonal than GR α_3 D H₄ species A at 143 cm or any other construct reported in this manuscript. The activity of GR α_3 D H₄ is also about half that of any of the other *de novo* constructs which one could explain by species B being an inactive form. However, the differences in activity observed are too minor to make definitive claims about the requirement of tetrahedral distortion for CuSOD activity. Future studies with other designed proteins may allow us to elucidate this relationship more clearly.

Cu(I)-protein XANES characterization

The XANES region of all four constructs were analyzed to investigate the coordination geometry. The Cu(I) 1s \rightarrow 4p transition at 8982-8985 eV, was analyzed to determine geometry differences between constructs. The intensity of this peak is indicative of coordination number with higher peak intensities correlating with lower coordination number.⁷³ GR α_3 D H₃D has the lowest 1s \rightarrow 4p transition signal, indicative of a higher coordination number (Figure 5). GR α_3 D H₃ and H₄ have similar

intermediate transition signals. GR α_3 D H₂DH has the highest transition signal, indicative of a lower coordination number, likely more 2-coordinate than 3-coordinate.




Figure 5. 1s \rightarrow 4p region of Cu(I) XANES at pH 7.5 for every construct reported.

Reduction potentials, affinity, and SOD activity

The apparent standard potentials of Cu(II)-complexes containing a C-terminal Cys (Ala98Cys) and grafted on a gold electrode are listed in Table 6 with cyclic voltammograms in Figure S3. All four constructs share similar first coordination sphere His₃N/O around the metal center as demonstrated by EXAFS analysis, however, the potential of GR α_3 D H₃ is notably higher than the other three at 550 mV vs. NHE compared to 420-470 mV vs. NHE. The reduction potentials of the four constructs lie in between the potentials for oxidation of superoxide to peroxide (-0.18 V vs.

Table 5. EPR parameters obtained from simulation of EPR spectra of Cu(II)-protein solutions.

		g_x	g_y	g_z	$A_{ }$ (10^{-4} cm ⁻¹)	$f=g_z/A_{ }$ (cm)
[a] GR α_3 D H ₃	75% A	2.05	2.04	2.27	166	136.8
	25% B	2.05	2.03	2.22	149	149.0
[a] GR α_3 D H ₄	50% A	2.012	2.04	2.26	158	143.0
	50% B	2.04	2.03	2.23	188	119.6
[a] GR α_3 D H ₂ DH	N/A	2.06	2.03	2.27	162	140.2
[a] GR α_3 D H ₃ D	N/A	2.04	2.04	2.26	168	134.5
[b] Cu-only SOD	N/A	2.05	2.05	2.26	~140	161.4
[c] Cu-(Fe) SOD	N/A	2.05	2.05	2.37	136	174.3

[a] X-band EPR spectra recorded at 100 K on solutions of 1 mM CuCl₂ and 2 mM protein in 50 mM HEPES buffer containing 30% glycerol at pH 7.5, 9.3 GHz, 20.5 mW, 1 G. [b] Spagnolo et al., J. Biol. Chem., 2004, 33447-33455. X-band EPR spectra of a Cu-only SOD from Mycobacterium tuberculosis [c] Kardinahl et al., Biol. Chem., 2000, 381, 1089-1101. X-band EPR spectra recorded at 10 K of a copper-substituted FeSOD from the archaeon Acidianus ambivalens in Tris/HCl buffer at pH 7, 9.6452 GHz, 20 mW, and 10.0 G.

NHE) and the reduction of superoxide to dioxygen (+0.91 V vs. NHE), which should enable catalysis of superoxide dismutation.

The Cu(II) affinities for each of these four constructs were determined in an effort to account for these differences in reduction potential (Table 6). Interestingly, though GR α_3 D H₃ has a much higher reduction potential, it does not have a Cu(II) affinity that is significantly different from that of GR α_3 D H₂DH and GR α_3 D H₃D. GR α_3 D H₄ has the weakest Cu(II) affinity with a K_d of 5.7×10^{-10} M, indicating that a fourth His residue does not play a significant role in the binding of Cu(II).

The calculated Cu(I) affinities vary by two orders of magnitude across the four constructs. Cu(I) binds tightest to GR α_3 D H₃, with a K_d of 1.22×10^{-16} M. GR α_3 D H₃D has an intermediate Cu(I) affinity (8.8×10^{-16} M), while both GR α_3 D H₄ and H₂DH have a weaker affinity at 4.1×10^{-15} and 5.4×10^{-15} M, respectively (Table 6). Thus, adding a fourth peptide ligand decreases the Cu(I) affinity of the protein but to different extents.

The SOD activities of the Cu-proteins were measured by the McCord-Fridovich assay,^{59,60} in which a secondary probe, XTT, is used to determine the amount of superoxide removed from solution by the SOD mimic.⁶¹ This assay is an indirect method to measure k_{cat} , but its reliability has been validated by direct methods (stopped-flow and pulse radiolysis).⁷⁴⁻⁷⁸ The assay was performed using an excess of ligand (4:1 protein/Cu(II) ratio) to ensure no free copper is present. The IC_{50} is the concentration of SOD mimics at which 50% of the superoxide produced is dismutated by the SOD mimics. From this value, the k_{McF} , which can be compared to a catalytic rate constant, is calculated (Table 6).^{2, 59, 60, 74-77} GR α_3 D H₃, GR α_3 D H₂DH, and GR α_3 D H₃D have similar IC_{50} (2.9-3.5 μ M) and k_{McF} (3×10^6 M⁻¹s⁻¹) values, whereas GR α_3 D H₄ has a lower SOD activity with the highest IC_{50} (8.0 μ M) and lowest k_{McF} (1.1×10^6 M⁻¹s⁻¹). The apo proteins showed no SOD activity in the same concentration range. Additional controls were performed to check that no reaction occurs between the complex and formazan, and that the complex did not inhibit xanthine oxidase.

Discussion

The Cu-only SOD models presented here demonstrate that an exact reproduction of the active site is not necessary for modest SOD activity, but that the native residues play an important role in mediating this activity. Previous work with Cu/Zn SODs has shown that loss of even a single histidine in the active site results in a loss of SOD activity, typically through a loss of copper binding.⁷⁹⁻⁸¹ While similar work in Cu only SODs has not been performed, the present work suggests that all four histidine residues are not necessary for copper binding or SOD activity.

Studies of the Cu(II) bound forms indicate that all four models are structurally similar to Cu only SOD. EPR experiments show that all four constructs are similar to both Cu(II) bound Cu only SOD and Cu(II) substituted FeSOD.^{7,82} The fourth protein ligand is not vital in modulating the structure of the Cu(II) binding environment as observed by EPR, but does determine how many species are present in solution. Both constructs with an Asp ligand contain a single species, while a fourth His ligand or lack of a fourth protein ligand results in two species. This is confirmed by CD for GR α_3 D H₄ as two unfolding steps are observed. Of these two species, only the more stable is observed upon cooling the sample. The fourth ligand, therefore, is necessary to restrict Cu(II) binding to only a single confirmation. A fourth aspartate ligand, regardless of position, may both coordinate the copper and orient a histidine residue in a single geometry. In both Cu/Zn and Cu only SODs, an aspartate ligand orients the histidine residue that is bound only in the Cu(II) form and loss of this residue results in a decrease in SOD activity.^{83,84} The second species present may simply be a result of different histidine coordination in these systems.

This is corroborated by the XAS data. While these experiments cannot distinguish between multiple coordination states, the average indicates that all three histidines are bound in all four constructs. The fourth residue is likely an additional histidine in GR α_3 D H₄ or an oxygen in the remaining three constructs. This oxygen may be from either the Asp ligand that is present in GR α_3 D H₃D or H₂DH or a solvent residue. Thus, the Asp may be binding the copper as a fourth residue or the Cu(II) coordination sphere is completed by water and the Asp acts solely to orient a histidine residue.

Table 6. Apparent standard potentials at pH 7.5, affinity constants and SOD activity of Cu(II)-protein complexes.

	$E_{1/2}$ ^[a] (mV vs. NHE)	Cu(II) K_d (10^{-10} M)	Cu(I) K_d (10^{-16} M)	IC_{50} ^[b] (μ M)	k_{McF} ^[b] (10^6 M ⁻¹ s ⁻¹)
GR α_3 D H ₃	550 \pm 10	5.00 \pm 0.17	1.22 \pm 0.04	2.9 \pm 0.6	3.0 \pm 0.6
GR α_3 D H ₄	463 \pm 10	5.7 \pm 0.3	41 \pm 2	8.0 \pm 1.7	1.1 \pm 0.2
GR α_3 D H ₂ DH	420 \pm 10	1.4 \pm 0.4	54 \pm 15	3.5 \pm 1.1	2.6 \pm 0.8
GR α_3 D H ₃ D	470 \pm 10	1.6 \pm 0.2	8.8 \pm 1.1	3.3 \pm 0.3	2.6 \pm 0.2

[a]The Cu(II)-proteins bearing a GSGC tail were grafted on an Au electrode and CV were recorded at $v = 0.05$ V/s in an electrochemical working cell containing 50 mM HEPES buffer, pH 7.5 at room temperature. CE: Pt wire, ref: SCE. [b] IC_{50} (μ M) and k_{McF} (10^6 M⁻¹s⁻¹) were determined from triplicate experiments with Cu(II)-protein (4:1 L/M) in 50 mM HEPES buffer, pH 7.5 with 100 μ M XTT, 200 μ M xanthine, and xanthine oxidase at 25 °C. $k_{XTT} = 8.6 \times 10^4$ M⁻¹s⁻¹ (in PBS 50 mM, pH 7.8). Note that the rate reported for GR α_3 D H₃ is a composite of two species as observed by EPR.

The Cu(II) affinity is also affected by this fourth ligand. GR α_3 D H₄ has the weakest Cu(II) affinity, though only slightly weaker than GR α_3 D H₃. If, however, the fourth ligand is instead an Asp residue, Cu(II) affinity increases by a factor of 3. The position of this Asp residue does not have a significant effect on the affinity of the cupric ion. This indicates that a fourth oxygen ligand lends to tighter Cu(II) binding than an imidazole ligand.

The fourth ligand is also important in modulating the copper reduction potential. Though all four constructs are catalytically active, GR α_3 D H₃ has a much higher reduction potential than the constructs with a fourth amino acid ligand. Simply adding a fourth ligand decreases the midpoint potential by 80–130 mV, depending on the construct. This may be by removing solvent from the active site or by limiting the amount of rearrangement necessary to convert between the Cu(I) and Cu(II) bound forms.⁸⁵ None of the constructs are close to the desired 360 mV vs NHE, the midpoint between the reduction and oxidation of superoxide.^{2, 3} Disrupting the His₃ plane decreases the reduction potential by 50 mV from ~470 to 420 mV vs NHE, even though the Cu(II) affinity remains unchanged between GR α_3 D H₃D and H₂DH. The rearrangement of the Asp residue does more to stabilize the Cu(II) bound enzyme outside of increasing the affinity for Cu(II). The axial His in GR α_3 D H₂DH is positioned in a more open, solvent exposed cavity, which may allow for easier conversion between the Cu(I) and Cu(II) forms than in GR α_3 D H₃D. In that construct the three histidines are located in a more spatially confined position within the peptide, preventing such easy rearrangement.

Calculated Cu(I) affinities also provide insight into the copper binding environment. Unsurprisingly given the relatively weak Cu(II) affinity and high reduction potential, GR α_3 D H₃ has the tightest Cu(I) affinity. GR α_3 D H₂DH has the weakest Cu(I) affinity, correlated with the low reduction potential and has the most two-coordinate character measured by XANES. Again, the identity and placement of the fourth ligand significantly affects cuprous binding. The identity of the axial ligand may account for this difference. With no axial peptide ligand (GR α_3 D H₃), Cu(I) binds with the highest affinity. In the Cu(II) bound form, the coordination sphere is completed with an axial solvent residue. This is most similar to GR α_3 D H₃D, containing an axial Asp residue in addition to the H₃ plane which results in an 8-fold loss in Cu(I) affinity. Maintaining the H₃ plane and adding an axial His residue (GR α_3 D H₄) further decreases the Cu(I) affinity (40x weaker than GR α_3 D H₃). Disruption of the His₃ plane results in the greatest loss of Cu(I) affinity and corresponds to the lowest reduction potential and highest Cu(II) affinity. Clearly, GR α_3 D H₂DH most favors the oxidized species.

All four constructs exhibit measurable SOD activity, though still three orders of magnitude slower than the native enzyme. They are more efficient than the previously reported manganese *de novo* mimic ($k_{\text{MCF}} = 3.7 \cdot 10^5 \text{ M}^{-1}\text{s}^{-1}$), and have a similar activity to the iron SOD mimic reported by Benson *et al.* ($k_{\text{cat}} 6.4 \cdot 10^6 \text{ M}^{-1}\text{s}^{-1}$).^{46–48} The slowest construct, GR α_3 D H₄, also has the weakest overall copper affinity which is known to decrease activity.^{79–81} The remaining three constructs are 2.5–3x faster but do not have statistically different rates. Thus, the trends in Cu(I/II) affinity and reduction potential do not correspond to trends in SOD activity. Previously, trends in reduction potential and SOD activity were observed for low-molecular weight manganese SOD mimics

which show a better SOD activity when the reduction potential is closer to 0.36 V vs. NHE, the midpoint potential between the oxidation and reduction of superoxide.^{1–3, 19, 20, 23} This observation applies for other copper SOD mimics.^{1–3, 19, 20, 22}

At this point we are unable to determine if these peptides are rate-limited by product release or conversion between the oxidized and reduced metal species. There may be a measurable difference in substrate conversion among the three more active peptides following the reduction potential trend that is unobservable due to slow product release.

To conclude, this study is the first example of the design of functional Cu only SOD mimics in *de novo* proteins and shows that all four His residues from the native active site are not required for SOD activity within a *de novo* construct. The activity of these constructs is much slower than that of the native enzyme and further studies will be done to address this. The Cu(I) environment and dynamics between the Cu(I) and Cu(II) bound species will be characterized to provide insight into this difference. These states could provide insight into the rate of catalysis and may highlight the importance of the fourth copper ligand. By modifying this fourth ligand, both in ligand type and position, we aim to improve the rate of catalysis and determine the most efficient coordination environment for SOD activity in *de novo* protein models.

Experimental Section

Protein expression and purification

pET15B recombinant DNA plasmid (Celtek Genes) containing the gene for the GR α_3 D constructs were transformed and expressed in *E. coli* BL21(DE3) competent cells (Life Technologies). The Ala98Cys derivatives of GR α_3 D constructs were prepared for electrochemical studies.

Colonies were inoculated in 30 mL of LB medium and 100 $\mu\text{g}\cdot\text{mL}^{-1}$ of ampicillin before being incubated at 37 °C and 175 rpm for 6–7 h. Autoincubation medium was inoculated with 10 mL/1L culture flask at 25 °C and 250 rpm for 18 h to overexpress the proteins. Cells were pelleted, resuspended in 1.0 mM phosphate buffer saline solution containing 2 mM dithiothreitol and 2 mM EDTA and lysed with a microfluidizer. The soluble protein was isolated after heat denaturation at 55 °C and acidification to pH 2 to remove contaminant proteins. The supernatant was syringe-filtered (0.2 μm) and purified on a reversed-phase C18 HPLC using a flow rate of 20 mL/min and a linear gradient of 0.1% TFA in 3:7 CH₃CN:H₂O to 0.1% TFA in 7:3 CH₃CN:H₂O over 35 min. The molecular weight of the purified peptide was confirmed by ESI-MS (collected on a Micromass LCT Time-of-Flight Mass Spectrometer) and found to correspond to the expected protein mass after deletion of the N-terminal methionine residue. Protein concentrations were determined by measuring the absorbance with $\epsilon_{280} = 8480 \text{ M}^{-1}\text{cm}^{-1}$.

Circular Dichroism (CD) Spectroscopy

CD spectra were collected on a Jasco J-1500 CD spectropolarimeter at 25 °C using 1 cm path length quartz cuvettes. Samples contained 10 mM phosphate buffer, pH 7.0,

and 10 μM protein. Cu(II) containing samples also included 11 μM CuCl_2 . Thermal denaturation samples were heated at at 5 $^\circ\text{C}/\text{min}$ and ellipticity was recorded every 5 $^\circ\text{C}$ from 25 to 100 degrees after stabilization within ± 0.1 $^\circ\text{C}$ of the desired temperature and an additional equilibration time of 5 minutes. Molar ellipticities ($[\theta]$) were calculated using previously reported procedures.^{63, 86, 87}

Cu(II) binding affinity

The binding affinity of Cu(II) to each peptide was determined using the competitive chelator 3,4-bis(oxamato)benzoic acid (baba). Solutions containing 50 μM peptide and 45 μM CuCl_2 in 50 mM HEPES pH 7.5 were titrated with 0.1 equivalents of baba with 10 minutes of equilibration time between additions. The reverse titration was also performed with 50 μM baba and 45 μM CuCl_2 in 50 mM HEPES pH 7.5. The absorbance of the Cu(II)baba complex was monitored at 330 nm and fit using previously described methods.⁸⁸

Cu(I) binding affinity

The binding affinity of Cu(I) was calculated at pH 7.5 based on the Cu(II) binding affinity and the reduction potentials of each peptide (Equation 1). A value of 0.159 V vs. NHE was used for $E^\circ_{(\text{Cu}^{\text{II}}, \text{aq})}$.^{89, 90}

$$E^\circ_{(\text{Cu}^{\text{I}}, \text{I}_{\text{pep}})} = E^\circ_{(\text{Cu}^{\text{II}}, \text{I}_{\text{aq}})} - \frac{2.303RT}{nF} \log \frac{Kd_{(\text{Cu}^{\text{I}})\text{I}_{\text{pep}}}}{Kd_{(\text{Cu}^{\text{II}})\text{I}_{\text{pep}}}}$$

Equation 1. Calculation of Cu(I) affinity from Cu(II) affinity and Cu^{II} standard potential

X-ray Absorption Spectroscopy

Cu(II) samples were prepared with 1.0 mM Cu(II)acetate and 1.5 mM peptide in a 50 mM HEPES buffer at pH 7.5 in aerobic conditions. Samples were then lyophilized before transferring to sample cells as a dried powder. During collection the Cu edge energy and $1s \rightarrow 4p$ transition of Cu(I)peptide were monitored. We estimate that no more than 10% of the sample was photoreduced in the scans included in fits.

Cu(I) samples were prepared with 1.0 mM tetrakis(acetonitrile)Cu(I)hexafluorophosphate and 1.5 mM peptide in a 50 mM HEPES buffer at pH 7.5 in anaerobic conditions. 50% glycerol was added to the solution as a glassing agent before sample solutions were loaded into an XAS sample cell and frozen in liquid nitrogen.

Measurements were carried out at Stanford Synchrotron Radiation Lightsource (SSRL) beamline 7-3 or 9-3 with a Si(220) double-crystal monochromator and a flat Rh-coated harmonic rejection mirror. Samples were maintained below 10 K with an Oxford Instruments liquid helium cryostat. Data were measured as fluorescence excitation spectra using a 30- or 100-element Ge detector array (for beamlines 7-3 or 9-3 respectively) normalized to incident intensity measured with a N_2 filled ion chamber. Data were measured with steps of 0.25 eV in the XANES region (1 sec integration time) and 0.05 \AA^{-1} in the EXAFS region to $k = 13.5 \text{\AA}^{-1}$ (1–20 sec integration, k^3 weighted). Energies were calibrated by assigning the lowest energy inflection point of a copper metal foil as 8980.3 eV. An initial E_0 value of 9000 eV was used to convert data to k -space, and the background was removed using a 3-

region cubic spline. EXAFS data were analysed using EXAFSPAK⁹¹ and FEFF 9.0.⁹² XANES data were normalized using MBACK.⁹³ For analysis of the $1s \rightarrow 3d$ transitions, data were fitted with an arctan background with a pseudo-Voigt peak to model the rising edge and the $1s \rightarrow 3d$ peak, and this fitted background was then subtracted from the data. Cu(I) spectra were analyzed in this way to determine the degree of oxidation of XAS samples. The absence of any peak above the noise in these spectra indicate that oxidation was minimal.

Single- and multiple-scattering fitting of EXAFS data were performed using EXAFSPAK⁹¹ with *ab initio* amplitude and phase parameters calculated using FEFF 9.0.⁹² An initial model of Cu-imidazole coordination was built based on the averaged bond distances determined by single-scattering fitting of EXAFS data. An initial model of Cu-imidazole coordination was built based on the average Cu-N bond distances determined by single-scattering fitting of EXAFS data, with the imidazole bond-lengths and angles taken as the average of all Cu-imidazole structures contained in the Cambridge Structural Database. All significant non-H paths, defined as those having an amplitude greater than 4% of the Cu-N amplitude, from this model were then loaded into EXAFSPAK and modeled as a rigid ligand. Initial estimates of the Debye-Waller factors for each Cu-imidazole shell were taken from calculations by Dimakis and Bunker.⁹⁴ The Cu-N distance and Debye-Waller factor were allowed to vary, with the distance and Debye-Waller factor for the other paths calculated based on the Cu-N values. Thus, the long distance scattering from the Cu-Imid was modeled while only varying two independent variables.

Electron Paramagnetic Resonance (EPR) spectroscopy

X-band EPR spectra were collected on a Bruker EMX electron spin resonance spectrometer with a Varian liquid nitrogen cryostat at 100 K. EPR samples contained 1 mM Cu(II) Cl_2 , 1.5–2 mM peptide, 50 mM HEPES pH 7.4, and 30% glycerol. Each sample was flash frozen in liquid N_2 before measurement. To obtain Cu(II) EPR parameters, each spectrum was simulated on SpinCount.⁶⁸

Electrochemistry

Cyclic voltammetry measurements were obtained on a Metrohm AUTOLAB potentiostat (PGSTAT302N). The electrochemical apparatus contained a gold (Au) disk working electrode (1 mm diameter), a platinum wire counter electrode, and an aqueous saturated calomel electrode (SCE) as the reference electrode (0.241 V + SCE = normal hydrogen electrode). The gold surface was polished with diamond slurries having decreasing particle sizes in the following order: 6–3–1 μm . Au electrodes were conditioned in an electrochemical cell containing 0.5 M H_2SO_4 , by scanning from –300 mV to +1500 mV vs. SCE at 500 mV/s until the cyclic voltammograms (CVs) overlaid to indicate a homogeneous surface. After each electrode had been polished and conditioned, 50 μL of a 0.5 mM Cu^{II} -protein Ala98Cys solution in 50 mM HEPES buffer pH 7.5 was chemically adsorbed on the Au surface for 2–3 h. CVs were

collected in 50 mM HEPES buffer, pH 7.5 at varying scan rates at room temperature (22–28 °C).

SOD activity

The SOD activity of the copper complexes was determined using the indirect assay of McCord-Fridovich observing XTT (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulphophenyl)-2H-Tetrazolium-5-Carboxanilide) reduction.^{59–61} Superoxide anions were generated by a xanthine-xanthine oxidase system and detected by monitoring the formation of formazan at 470 nm. The reactions were performed in 50 mM HEPES buffer pH 7.4 with 100 μ M XTT and 200 μ M xanthine. An appropriate amount of xanthine oxidase was added to start the reaction and generate a change in absorbance of 0.025–0.030 min^{-1} . The absorbance at 470 nm was monitored for 1.5 minutes (slope P1) before the addition of the SOD mimic, and for another 1.5 minutes after the addition (slope P2). Plot of the ratio (P1–P2)/P1 as a function of SOD mimic concentration is used to calculate the inhibition concentration (IC_{50}) at which the reduction of XTT to formazan is inhibited by 50% ($\text{P2} = \frac{1}{2} \text{P1}$). A pseudo-catalytic rate constant, k_{McF} , is deduced from the IC_{50} value using the relation: $k_{\text{XTT}} \times [\text{XTT}] = (k_{\text{McF}})(\text{IC}_{50})$, with $k_{\text{XTT}} = 5.94 \times 10^4 \text{ M}^{-1}\text{s}^{-1}$ (pH 7.8).² In order to ensure that no free copper is present in solution the experiments were performed with an excess of protein (4:1 protein/metal ratio). The measurements were performed in triplicate for each compound. Controls with the apo-proteins show no SOD activity. Controls were performed to determine that no inhibition of the xanthine-xanthine oxidase system resulted from the addition of the peptides. The rate of conversion of xanthine to urate was monitored at 290 nm in the presence and absence of peptide and no inhibition was observed. Possible formazan complexation was monitored at 490 nm after the addition of peptide and no decrease in absorbance was detected, indicating no inhibition.^{95–97}

Acknowledgements

VP, KK, and AT thank NIH grant R01 ES012236 for funding. AT additionally acknowledges the Chateaubriand Fellowship for funding. CP and EM acknowledge the network FrenchBIC (<http://frenchbic.cnrs.fr/>) for EM's fellowship for her stay at Michigan. They also wish to thank ANR (ANR-15-CE07-0027) and Fondation pour la recherche médicale (DIE20151234413) for funding. OI acknowledges the financial support from Fundação para a Ciência e a Tecnologia [PTDC/QUI-BIQ/098406/2008] and the Marie Curie Actions (FP7-PEOPLE-IRG-230896).

Keywords: bioinorganic chemistry • enzyme models • metalloenzymes • metalloproteins • protein design

1. Y. Sheng, I. A. Abreu, D. E. Cabelli, M. J. Maroney, A.-F. Miller, M. Teixeira and J. S. Valentine, *Chem. Rev.*, 2014, **114**, 3854–3918.
2. C. Policar, in *Redox Active Therapeutics*, eds. J. S. Rebouças, I. Batinic-Haberle, I. Spasojevic, D. S. Warner and D. St. Clair, Springer, 2016, ch. Chapter 17, pp. 125–164.
3. I. A. Abreu and D. E. Cabelli, *Biochim. Biophys. Acta*, 2010, **1804**, 263–274.
4. J. D. Aguirre and V. C. Culotta, *J. Biol. Chem.*, 2012, **287**, 13541–13548.
5. D. P. Barondeau, C. J. Kassmann, C. K. Bruns, J. A. Tainer and E. D. Getzoff, *Biochemistry*, 2004, **43**, 8038–8047.
6. J. E. Gleason, A. Galalaldeen, R. L. Peterson, A. B. Taylor, S. P. Holloway, J. Waninger-Saroni, B. P. Cormack, D. E. Cabelli, P. J. Hart and V. C. Culotta, *Proceedings of the National Academy of Sciences*, 2014, **111**, 5866–5871.
7. L. Spagnolo, I. Törö, M. D'Orazio, P. O'Neill, J. Z. Pedersen, O. Carugo, G. Rotilio, A. Battistoni and K. Djinić-Carugo, *J. Biol. Chem.*, 2004, **279**, 33447–33455.
8. C. X. Li, J. E. Gleason, S. X. Zhang, V. M. Bruno, B. P. Cormack and V. C. Culotta, *Proceedings of the National Academy of Sciences*, 2015, **112**, E5336–E5342.
9. N. G. Robinett, R. L. Peterson and V. C. Culotta, *Journal of Biological Chemistry*, 2018, **293**, 4636–4643.
10. R. L. Peterson, A. Galalaldeen, J. Villarreal, A. B. Taylor, D. E. Cabelli, P. J. Hart and V. C. Culotta, *Journal of Biological Chemistry*, 2016, **291**, 20911–20923.
11. J. E. Gleason, A. Galalaldeen, R. L. Peterson, A. B. Taylor, S. P. Holloway, J. Waninger-Saroni, B. P. Cormack, D. E. Cabelli, P. J. Hart and V. C. Culotta, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 5866–5871.
12. H. J. Forman and I. Fridovich, *Arch. Biochem. Biophys.*, 1973, **158**, 396–400.
13. S. B. Choudhury, J.-W. Lee, G. Davidson, Y.-I. Yim, K. Bose, M. L. Sharma, S.-O. Kang, D. E. Cabelli and M. J. Maroney, *Biochemistry*, 1999, **38**, 3744–3752.
14. Y.-H. Zhou, H. Fu, W.-X. Zhao, W.-L. Chen, C.-Y. Su, H. Sun, L.-N. Ji and Z.-W. Mao, *Inorg. Chem. (Washington, DC, U. S.)*, 2007, **46**, 734–739.
15. D. Árus, A. Jancsó, D. Szunyogh, F. Matyuska, N. V. Nagy, E. Hoffmann, T. Körtvéyesi and T. Gajda, *J. Inorg. Biochem.*, 2012, **106**, 10–18.
16. D. P. Riley, *Chem. Rev.*, 1999, **99**, 2573–2588.
17. D. Salvemini, C. Muscoli, D. P. Riley and S. Cuzzocrea, *Pulm. Pharmacol. Ther.*, 2002, **15**, 439–447.
18. O. Iranzo, *Bioorg. Chem.*, 2011, **39**, 73–87.
19. I. Batinic-Haberle, A. Tovmasyan, E. R. Roberts, Z. Vujaskovic, K. W. Leong and I. Spasojevic, *Antioxid. Redox Signal.*, 2014, **20**, 2372–2415.
20. I. Batinic-Haberle, J. S. Rebouças and I. Spasojević, *Antioxid. Redox Signaling*, 2010, **13**, 877–918.
21. D. Salvemini, C. Muscoli, D. P. Riley and S. Cuzzocrea, *Pulm. Pharmacol. Ther.*, 2002, **15**, 439–447.
22. R. P. Bonomo, G. Impellizzeri, D. La Mendola, G. Maccarrone, G. Pappalardo, A. Santoro, G. Tabbi, G. Vecchio and E. Rizzarelli, in *Metal-ligand interactions. Molecular, nano-, micro- and macro-systems in complex environments*, eds. N. Russo, D. R. Salahub and M. Witko, Kluwer Academic Publishers, Dordrecht; Boston; London, 2003, pp. 41–63.
23. I. Batinic-Haberle, A. Tovmasyan and I. Spasojevic, *Antioxid. Redox Signal.*, 2018, **29**, 1691–1724.
24. I. Batinic-Haberle and M. E. Tome, *Redox Biol.*, 2019, DOI: 10.1016/j.redox.2019.101139, 101139.
25. Y.-H. Zhou, H. Fu, W.-X. Zhao, W.-L. Chen, C.-Y. Su, H. Sun, L.-N. Ji and Z.-W. Mao, *Inorganic Chemistry*, 2007, **46**, 734–739.
26. J.-J. Zhang, Q.-H. Luo, D.-L. Long, J.-T. Chen, F.-M. Li and A.-D. Liu, *Journal of the Chemical Society, Dalton Transactions*, 2000, DOI: 10.1039/a909018e, 1893–1900.
27. C.-J. Feng, Q.-H. Luo, Z.-L. Wang, M.-C. Shen, H.-W. Wang and M.-H. Zhao, *J. Inorg. Biochem.*, 1999, **75**, 1–6.

28. A. Kotynia, T. Janek, Ż. Czyżnikowska, S. Bielińska, W. Kamysz and J. Brasuń, *Int. J. Pept. Res. Ther.*, 2017, **23**, 431-439.
29. G. Csire, S. Timári, J. Asztalos, J. M. Király, M. Kiss and K. Várnagy, *J. Inorg. Biochem.*, 2017, **177**, 198-210.
30. S. Timári, R. Cerea and K. Várnagy, *J. Inorg. Biochem.*, 2011, **105**, 1009-1017.
31. I. N. Jakab, O. Lórinz, A. Jancsó, T. Gajda and B. Gyurcsik, *Dalton Trans.*, 2008, DOI: 10.1039/b811452h, 6987.
32. A. Jancsó, Z. Paksi, N. Jakab, B. Gyurcsik, A. Rockenbauer and T. Gajda, *Dalton Trans.*, 2005, DOI: 10.1039/b507655b, 3187.
33. B. Bóka, A. Myari, I. Sóvágó and N. Hadjilidis, *J. Inorg. Biochem.*, 2004, **98**, 113-122.
34. L. L. Costanzo, G. D. Guidi, S. Giuftida, E. Rizzarelli and G. Vecchio, *J. Inorg. Biochem.*, 1993, **50**, 273-281.
35. S. Kubota and J. T. Yang, *Proceedings of the National Academy of Sciences*, 1984, **81**, 3283-3286.
36. R. Brigelius, R. Spöttl, W. Bors, E. Lengfelder, M. Saran and U. Weser, *FEBS Lett.*, 1974, **47**, 72-75.
37. P.-S. Huang, S. E. Boyken and D. Baker, *Nature*, 2016, **537**, 320-327.
38. J. W. Bryson, S. F. Betz, H. S. Lu, D. J. Suich, H. X. Zhou, K. T. O'Neil and W. F. DeGrado, *Science*, 1995, **270**, 935-941.
39. J. W. Bryson, J. R. Desjarlais, T. M. Handel and W. F. DeGrado, *Protein Science*, 1998, **7**, 1404-1414.
40. W. F. DeGrado, a. C. M. Summa, V. Pavone, F. Nastro and a. A. Lombardi, *Annu. Rev. Biochem.*, 1999, **68**, 779-819.
41. J. S. Plegaria and V. L. Pecoraro, *Israel Journal of Chemistry*, 2015, **55**, 85-95.
42. M. Tegoni, *Eur. J. Inorg. Chem.*, 2014, **2014**, 2177-2193.
43. D. Ghosh and V. L. Pecoraro, *Curr. Opin. Chem. Biol.*, 2005, **9**, 97-103.
44. F. Yu, V. M. Cangelosi, M. L. Zastrow, M. Tegoni, J. S. Plegaria, A. G. Tebo, C. S. Mocny, L. Ruckthong, H. Qayyum and V. L. Pecoraro, *Chemical Reviews*, 2014, **114**, 3495-3578.
45. M. L. Zastrow and V. L. Pecoraro, *Coordination Chemistry Reviews*, 2013, **257**, 2565-2588.
46. U. P. Singh, R. K. Singh, Y. Isogai and Y. Shiro, *Int. J. Pept. Res. Ther.*, 2006, **12**, 379-385.
47. A. L. Pinto, H. W. Hellinga and J. P. Caradonna, *Proceedings of the National Academy of Sciences*, 1997, **94**, 5562-5567.
48. D. E. Benson, M. S. Wisz and H. W. Hellinga, *Proceedings of the National Academy of Sciences*, 2000, **97**, 6292-6297.
49. J. W. Bryson, J. R. Desjarlais, T. M. Handel and W. F. DeGrado, *Protein Sci.*, 1998, **7**, 1404-1414.
50. S. T. R. Walsh, H. Cheng, J. W. Bryson, H. Roder and W. F. DeGrado, *Proc. Natl. Acad. Sci. U. S. A.*, 1999, **96**, 5486-5491.
51. J. W. Bryson, S. F. Betz, H. S. Lu, D. J. Suich, H. X. Zhou, K. T. O'Neil and W. F. DeGrado, *Science*, 1995, **270**, 935-941.
52. V. M. Cangelosi, A. Deb, J. E. Penner-Hahn and V. L. Pecoraro, *Angewandte Chemie International Edition*, 2014, **53**, 7900-7903.
53. J. S. Plegaria, M. Duca, C. Tard, T. J. Friedlander, A. Deb, J. E. Penner-Hahn and V. L. Pecoraro, *Inorg. Chem.*, 2015, **54**, 9470-9482.
54. J. S. Plegaria, S. P. Dzul, E. R. P. Zuiderweg, T. L. Stemmler and V. L. Pecoraro, *Biochemistry*, 2015, **54**, 2858-2873.
55. A. G. Tebo, A. Quaranta, C. Herrero, V. L. Pecoraro and A. Aukauloo, *ChemPhotoChem*, 2017, **1**, 89-92.
56. A. G. Tebo, T. B. J. Pinter, R. Garcia-Serres, A. L. Speelman, C. Tard, O. Seneque, G. Blondin, J. M. Latour, J. Penner-Hahn, N. Lehnert and V. L. Pecoraro, *Biochemistry*, 2018, **57**, 2308-2316.
57. K. J. Koebeke, F. Yu, E. Salerno, C. Van Stappen, A. G. Tebo, J. E. Penner-Hahn and V. L. Pecoraro, *Angew. Chem. Int. Ed. Engl.*, 2018, DOI: 10.1002/anie.201712757.
58. K. J. Koebeke, L. Ruckthong, J. L. Meagher, E. Mathieu, J. Harland, A. Deb, N. Lehnert, C. Policar, C. Tard, J. E. Penner-Hahn, J. A. Stuckey and V. L. Pecoraro, *Inorg. Chem.*, 2018, **57**, 12291-12302.
59. I. Fridovich, *J. Biol. Chem.*, 1970, **245**, 4053-4057.
60. J. M. McCord and I. Fridovich, *J. Biol. Chem.*, 1969, **244**, 6049-6055.
61. M. W. Sutherland and B. A. Learmonth, *Free Radical Res.*, 1997, **27**, 283-289.
62. Y.-H. Chen, J. T. Yang and K. H. Chau, *Biochemistry*, 1974, **13**, 3350-3359.
63. T. E. Creighton, *Protein structure. A practical approach*, Oxford University Press, New York, 1997.
64. N. J. Greenfield, *Nat. Protoc.*, 2007, **1**, 2527-2535.
65. M. Niklasson, C. Andresen, S. Helander, M. G. Roth, A. Zimdahl Kahlin, M. Lindqvist Appell, L. G. Martensson and P. Lundstrom, *Protein Sci.*, 2015, **24**, 2055-2062.
66. J. E. Hahn, R. A. Scott, K. O. Hodgson, S. Doniach, S. R. Desjardins and E. I. Solomon, *Chem. Phys. Lett.*, 1982, **88**, 595-598.
67. G. Frank de, V. György and G. Pieter, *J. Phys.: Condens. Matter*, 2009, **21**, 104207.
68. A. P. Golombek and M. P. Hendrich, *J. Magn. Reson.*, 2003, **165**, 33-48.
69. E. I. Solomon, D. E. Heppner, E. M. Johnston, J. W. Ginsbach, J. Cirera, M. Qayyum, M. T. Kieber-Emmons, C. H. Kjaergaard, R. G. Hadt and L. Tian, *Chem. Rev.*, 2014, **114**, 3659-3853.
70. S. Kardinahl, S. Anemüller and G. Schäfer, *Biol. Chem.*, 2000, **381**.
71. U. Sakaguchi and A. W. Addison, *J. Chem. Soc., Dalton Trans.*, 1979, DOI: 10.1039/DT9790000600, 600-608.
72. A. Diaz, R. Pogni, R. Cao and R. Basosi, *Inorg. Chim. Acta*, 1998, **275-276**, 552-556.
73. L. S. Kau, D. J. Spira-Solomon, J. E. Penner-Hahn, K. O. Hodgson and E. I. Solomon, *J. Am. Chem. Soc.*, 1987, **109**, 6433-6442.
74. M. Eckshtain, I. Zilbermann, A. Mahammed, I. Saltsman, Z. Okun, E. Maimon, H. Cohen, D. Meyerstein and Z. Gross, *Dalton Trans.*, 2009, DOI: 10.1039/B911278B, 7879-7882.
75. I. Spasojevic, I. Batinic-Haberle, R. D. Stevens, P. Hambright, A. N. Thorpe, J. Grodkowski, P. Neta and I. Fridovich, *Inorg. Chem.*, 2001, **40**, 726-739.
76. S. Durot, C. Policar, F. Cisnetti, F. Lambert, J.-P. Renault, G. Pelosi, G. Blain, H. Korri-Yousoufi and J.-P. Mahy, *Eur. J. Inorg. Chem.*, 2005, 3513-3523.
77. S. Durot, F. Lambert, J.-P. Renault and C. Policar, *Eur. J. Inorg. Chem.*, 2005, 2789-2793.
78. F. C. Friedel, D. Lieb and I. Ivanovic-Burmazovic, *Journal of Inorganic Biochemistry*, 2012, **109**, 26-32.
79. M. T. Carri, A. Battistonia, F. Polizio, A. Desideri and G. Rotilio, *FEBS J.*, 1994, **356**, 314-316.
80. J. Wang, H. Slunt, V. Gonzales, D. Fromholt, M. Coonfield, N. G. Copeland, N. A. Jenkins and D. R. Borchelt, *Hum. Mol. Genet.*, 2003, **12**, 2753-2764.
81. J. Wang, A. Caruano-Yzermans, A. Rodriguez, J. P. Scheurmann, H. H. Slunt, X. Cao, J. Gitlin, P. J. Hart and D. R. Borchelt, *J. Biol. Chem.*, 2007, **282**, 345-352.
82. S. Kardinahl, S. Anemüller and G. Schafer, *Biol. Chem.*, 2000, **381**, 1089-1101.
83. R. L. Peterson, A. Galaldeeden, J. Villarreal, A. B. Taylor, D. E. Cabelli, P. J. Hart and V. C. Culotta, *J. Biol. Chem.*, 2016, **291**, 20911-20923.

-
84. C. L. Fisher, D. E. Cabelli, J. A. Tainer, R. A. Hallewell and E. D. Getzoff, *Proteins Struct. Funct. Bioinform.*, 1994, **19**, 24-34.
85. G. R. Moore, G. W. Pettigrew and N. K. Rogers, *Proceedings of the National Academy of Sciences*, 1986, **83**, 4998-4999.
86. C. A. Rohl and R. L. Baldwin, *Biochemistry*, 1997, **36**, 8435-8442.
87. P. Luo and R. L. Baldwin, *Biochemistry*, 1997, **36**, 8413-8421.
88. A. Conte-Daban, V. Borghesani, S. Sayen, E. Guillon, Y. Journaux, G. Gontard, L. Lisnard and C. Hureau, *Anal. Chem.*, 2017, **89**, 2155-2162.
89. M. Tegoni, F. Yu, M. Bersellini, J. E. Penner-Hahn and V. L. Pecoraro, *Proceedings of the National Academy of Sciences*, 2012, **109**, 1-6.
90. P. Atkins, T. Overton, J. Rourke, M. Weller, F. Armstrong and M. Hagerman, *Inorganic Chemistry*, Oxford University Press, W. H. Freeman and Company, New York, Fifth Edition edn., 2010.
91. G. N. George and I. J. Pickering, EXAFSPAK, <http://ssrl.siac.stanford.edu/~george/exafspak/exafs.htm>.
92. A. L. Ankudinov and J. J. Rehr, *Physical Review B*, 1997, **56**, R1712-R1716.
93. T.-C. Weng, G. S. Waldo and J. E. Penner-Hahn, *Journal of Synchrotron Radiation*, 2005, **12**, 506-510.
94. N. Dimakis and G. Bunker, *Physical Review B*, 2004, **70**, 195114.
95. F. C. Friedel, D. Lieb and I. Ivanović-Burmazović, *Journal of Inorganic Biochemistry*, 2012, **109**, 26-32.
96. K. M. Faulkner, S. I. Liochev and I. Fridovich, *J. Biol. Chem.*, 1994, **269**, 23471-23476.
97. R. H. Weiss, A. G. Flickinger, W. J. Rivers, M. M. Hardy, K. W. Aston, U. S. Ryan and D. P. Riley, *J. Biol. Chem.*, 1993, **268**, 23049-23054.
-